Karagöz Bülent, Özgün Alpaslan, Emirzeoğlu Levent, Tunçel Tolga, Çelik Serkan, Bilgi Oğuz, Kara Kemal
Clinic of Oncology, Gülhane Military Medical Academy, Haydarpaşa Training and Research Hospital, İstanbul, Turkey.
Clinic of Radiology, Gülhane Military Medical Academy, Haydarpaşa Training and Research Hospital, İstanbul, Turkey.
J Breast Health. 2015 Jan 1;11(1):48-51. doi: 10.5152/tjbh.2014.2009. eCollection 2015 Jan.
Lapatinib is an effective drug in HER2-positive breast cancer. We present a case with successful treatment of lapatinib in brain metastasis of HER2+ breast cancer. Forty-eight years old woman was admitted our clinic with early breast cancer. In third years after adjuvant chemotherapy and trastuzumab, isolated and multiple brain metastasis were detected. After whole brain RT, lapatinib (with capecitabine for 10 months and with letrozole for 3 months) has been used. Volumetric reduction of lesions was achieved and symptoms disappeared. When lapatinib discontinued, brain metastasis relapses. Lapatinib plus capecitabine reinduction has been started. Totally, longer survival than 45 months was achieved after first brain metastasis detection. Because both combinations of lapatinib with capecitabine and letrozole were effective and reinduction treatment was successful, presented case has strongly supported activity of lapatinib treatment in brain metastasis of HER2+ breast cancer.
拉帕替尼是治疗HER2阳性乳腺癌的一种有效药物。我们报告了1例成功使用拉帕替尼治疗HER2+乳腺癌脑转移的病例。一名48岁女性因早期乳腺癌入住我院。在辅助化疗和曲妥珠单抗治疗3年后，检测到孤立性和多发性脑转移。全脑放疗后，使用了拉帕替尼（与卡培他滨联合使用10个月，与来曲唑联合使用3个月）。实现了病灶体积缩小且症状消失。当停用拉帕替尼时，脑转移复发。已开始重新使用拉帕替尼加卡培他滨诱导治疗。自首次检测到脑转移后，总体生存期超过了45个月。由于拉帕替尼与卡培他滨及来曲唑的联合使用均有效且重新诱导治疗成功，本病例有力地支持了拉帕替尼治疗HER2+乳腺癌脑转移的有效性。
